Free Technical Research on Nektar Therapeutics and Three More Biotech Equities

Stock Research Monitor: IBIO, IDRA, and OGEN

LONDON, UK / ACCESSWIRE / June 27, 2018 / If you want a free Stock Review on NKTR sign up now at www.wallstequities.com/registration. On Tuesday, June 26, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday’s trading session in bullish territories. Taking into consideration yesterday’s market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: iBio Inc. (NYSE AMER: IBIO), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Nektar Therapeutics (NASDAQ: NKTR), and Oragenics Inc. (NYSE AMER: OGEN). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

iBio

On Tuesday, shares in New York-based iBio Inc. recorded a trading volume of 398,385 shares, which was higher than their three months average volume of 138.32 thousand shares. The stock ended at $0.9, rising 4.65% from the last trading session. The stock is trading below its 50-day moving average by 38.33%. Furthermore, shares of iBio, which focuses on developing and commercializing pharmaceutical product applications using its platform in the US and internationally, have a Relative Strength Index (RSI) of 27.55. Get the full research report on IBIO for free by clicking below at:

www.wallstequities.com/registration/?symbol=IBIO

Idera Pharmaceuticals

Cambridge, Massachusetts-based Idera Pharmaceuticals Inc.’s stock finished yesterday’s session 0.78% higher at $1.29. A total volume of 1.93 million shares was traded, which was above their three months average volume of 1.50 million shares. The stock is trading below its 50-day moving average by 26.47%. Furthermore, shares of Idera Pharma, which focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the US, have an RSI of 26.41. Get access to our top-rated research, including the free report on IDRA at:

www.wallstequities.com/registration/?symbol=IDRA

Nektar Therapeutics

At the close of trading on Tuesday, shares in San Francisco, California headquartered Nektar Therapeutics saw a drop of 2.85%, ending the day at $49.81. The stock recorded a trading volume of 6.10 million shares, which was higher than its three months average volume of 4.19 million shares. The Company’s shares have advanced 152.39% over the last twelve months. The stock is trading below its 50-day moving average by 33.00%. Moreover, shares of Nektar Therapeutics, which discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the US, have an RSI of 32.53.

On June 11th, 2018, research firm H.C. Wainwright downgraded the Company’s stock rating from ‘Buy’ to ‘Neutral’, with a target price of $54 per share. Click here to subscribe for a free membership which welcomes you with our report on NKTR at:

www.wallstequities.com/registration/?symbol=NKTR

Oragenics

Tampa, Florida headquartered Oragenics Inc.’s shares ended the day 0.66% lower at $1.52 with a total trading volume of 41,816 shares. The stock has gained 27.62% in the last month. The Company’s shares are trading above their 50-day moving average by 7.50%. Additionally, shares of Oragenics, which focuses on developing antibiotics against infectious diseases and treatments for oral mucositis, have an RSI of 52.35. To get free access to your research report on OGEN, sign up at:

www.wallstequities.com/registration/?symbol=OGEN

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 503843